-
All Events
IAO-EAO-SIdP joint meeting 2024EAO-DGI joint meeting 202329th Annual Scientific CongressEAO Digital Days 2021EAO Digital Days 202028th Annual Scientific Congress27th Annual Scientific Congress26th Annual Scientific Congress25th Annual Scientific Congress24th Annual Scientific Congress23rd Annual Scientific Congress -
All Content TypesAbstractArticle ReviewePosterLearning moduleLearning QuizMatching SlidePDF DocumentWebcast
-
Sort ByRelevance
Background
Different approaches have been reported to augment the maxillary sinus cavity of severely atrophied posterior maxilla, with simultaneous or delayed installation of the implants.However, Schneiderian membrane perforations, nose bleeding, postoperative pain, swelling, hematoma and possible sinus infection could be considered as major risks.
Aim/Hypothesis
To evaluate clinical and radiological outcomes of a novel device that allows hydraulic Schneiderian membrane elevation, bone grafting and implant placement at the same time.
Material and Methods
Eight-teen consecutive participants with a severe atrophy of the posterior maxilla underwent transcrestal elevation of the sinus membrane and implant placement. At the 6-month follow-up the following parameters were assessed: implant success, any complications, marginal bone loss (MBL), tridimensional graft measurements, implant stability quotient (ISQ), and graft density.
Results
No implants failed during follow-up (10.8±2.8 months, range 7-14). No membrane tears and no other adverse events were observed. Mean residual alveolar ridge height was 4.78±0.88 mm. Six-month after procedure, mean MBL was 0.18 mm. The mean sinus membrane elevation was 12.78±2.18 mm (range 10.7-14.23). Along the basic three-dimensional reference planes, the grafted bone, measured around implants was: axial area, 239.7±57.68 mm2; sagittal area, 257.0±60.83 mm2; coronal area, 143.3±29.46 mm2. The mean volume of the graft was 2.38±0.26 CC at the baseline and 2.05±0.24 CC six months after graft maturation (difference: 0.33±0.29 CC, P=.0090). Graft density, converted in Hounsfield Unit (HU), improved during healing from 322.0±100.42 HU to 1062.0±293.7 HU; difference 740.0±295.35 HU (P=0.0001). The mean ISQ value was 65.5 at implant placement and it increased to 74.1 at the 6-month examination (P=.0014). Twelve out of 18 patients (66.6%) experienced no pain; 10 out of 18 patient experienced no swelling (55.5%). No severe pain or swelling was reported in all of the cases. The mean analgesic tables consuming was 0.78±0.67. Mean surgical time was 24.0±4.07 minutes.
Conclusions and clinical implications
The iRaise Sinus Lift System may provide a new option for minimally invasive transcrestal sinus surgery with minimal patient discomfort. A physiological contraction of 13.9% of its original volume was experienced during healing. Long term clinical studies are needed to confirm these preliminary results.
Background
Different approaches have been reported to augment the maxillary sinus cavity of severely atrophied posterior maxilla, with simultaneous or delayed installation of the implants.However, Schneiderian membrane perforations, nose bleeding, postoperative pain, swelling, hematoma and possible sinus infection could be considered as major risks.
Aim/Hypothesis
To evaluate clinical and radiological outcomes of a novel device that allows hydraulic Schneiderian membrane elevation, bone grafting and implant placement at the same time.
Material and Methods
Eight-teen consecutive participants with a severe atrophy of the posterior maxilla underwent transcrestal elevation of the sinus membrane and implant placement. At the 6-month follow-up the following parameters were assessed: implant success, any complications, marginal bone loss (MBL), tridimensional graft measurements, implant stability quotient (ISQ), and graft density.
Results
No implants failed during follow-up (10.8±2.8 months, range 7-14). No membrane tears and no other adverse events were observed. Mean residual alveolar ridge height was 4.78±0.88 mm. Six-month after procedure, mean MBL was 0.18 mm. The mean sinus membrane elevation was 12.78±2.18 mm (range 10.7-14.23). Along the basic three-dimensional reference planes, the grafted bone, measured around implants was: axial area, 239.7±57.68 mm2; sagittal area, 257.0±60.83 mm2; coronal area, 143.3±29.46 mm2. The mean volume of the graft was 2.38±0.26 CC at the baseline and 2.05±0.24 CC six months after graft maturation (difference: 0.33±0.29 CC, P=.0090). Graft density, converted in Hounsfield Unit (HU), improved during healing from 322.0±100.42 HU to 1062.0±293.7 HU; difference 740.0±295.35 HU (P=0.0001). The mean ISQ value was 65.5 at implant placement and it increased to 74.1 at the 6-month examination (P=.0014). Twelve out of 18 patients (66.6%) experienced no pain; 10 out of 18 patient experienced no swelling (55.5%). No severe pain or swelling was reported in all of the cases. The mean analgesic tables consuming was 0.78±0.67. Mean surgical time was 24.0±4.07 minutes.
Conclusions and clinical implications
The iRaise Sinus Lift System may provide a new option for minimally invasive transcrestal sinus surgery with minimal patient discomfort. A physiological contraction of 13.9% of its original volume was experienced during healing. Long term clinical studies are needed to confirm these preliminary results.
Background
Different approaches have been reported to augment the maxillary sinus cavity of severely atrophied posterior maxilla, with simultaneous or delayed installation of the implants.However, Schneiderian membrane perforations, nose bleeding, postoperative pain, swelling, hematoma and possible sinus infection could be considered as major risks.
Aim/Hypothesis
To evaluate clinical and radiological outcomes of a novel device that allows hydraulic Schneiderian membrane elevation, bone grafting and implant placement at the same time.
Material and Methods
Eight-teen consecutive participants with a severe atrophy of the posterior maxilla underwent transcrestal elevation of the sinus membrane and implant placement. At the 6-month follow-up the following parameters were assessed: implant success, any complications, marginal bone loss (MBL), tridimensional graft measurements, implant stability quotient (ISQ), and graft density.
Results
No implants failed during follow-up (10.8±2.8 months, range 7-14). No membrane tears and no other adverse events were observed. Mean residual alveolar ridge height was 4.78±0.88 mm. Six-month after procedure, mean MBL was 0.18 mm. The mean sinus membrane elevation was 12.78±2.18 mm (range 10.7-14.23). Along the basic three-dimensional reference planes, the grafted bone, measured around implants was: axial area, 239.7±57.68 mm2; sagittal area, 257.0±60.83 mm2; coronal area, 143.3±29.46 mm2. The mean volume of the graft was 2.38±0.26 CC at the baseline and 2.05±0.24 CC six months after graft maturation (difference: 0.33±0.29 CC, P=.0090). Graft density, converted in Hounsfield Unit (HU), improved during healing from 322.0±100.42 HU to 1062.0±293.7 HU; difference 740.0±295.35 HU (P=0.0001). The mean ISQ value was 65.5 at implant placement and it increased to 74.1 at the 6-month examination (P=.0014). Twelve out of 18 patients (66.6%) experienced no pain; 10 out of 18 patient experienced no swelling (55.5%). No severe pain or swelling was reported in all of the cases. The mean analgesic tables consuming was 0.78±0.67. Mean surgical time was 24.0±4.07 minutes.
Conclusions and clinical implications
The iRaise Sinus Lift System may provide a new option for minimally invasive transcrestal sinus surgery with minimal patient discomfort. A physiological contraction of 13.9% of its original volume was experienced during healing. Long term clinical studies are needed to confirm these preliminary results.
Background
Different approaches have been reported to augment the maxillary sinus cavity of severely atrophied posterior maxilla, with simultaneous or delayed installation of the implants.However, Schneiderian membrane perforations, nose bleeding, postoperative pain, swelling, hematoma and possible sinus infection could be considered as major risks.
Aim/Hypothesis
To evaluate clinical and radiological outcomes of a novel device that allows hydraulic Schneiderian membrane elevation, bone grafting and implant placement at the same time.
Material and Methods
Eight-teen consecutive participants with a severe atrophy of the posterior maxilla underwent transcrestal elevation of the sinus membrane and implant placement. At the 6-month follow-up the following parameters were assessed: implant success, any complications, marginal bone loss (MBL), tridimensional graft measurements, implant stability quotient (ISQ), and graft density.
Results
No implants failed during follow-up (10.8±2.8 months, range 7-14). No membrane tears and no other adverse events were observed. Mean residual alveolar ridge height was 4.78±0.88 mm. Six-month after procedure, mean MBL was 0.18 mm. The mean sinus membrane elevation was 12.78±2.18 mm (range 10.7-14.23). Along the basic three-dimensional reference planes, the grafted bone, measured around implants was: axial area, 239.7±57.68 mm2; sagittal area, 257.0±60.83 mm2; coronal area, 143.3±29.46 mm2. The mean volume of the graft was 2.38±0.26 CC at the baseline and 2.05±0.24 CC six months after graft maturation (difference: 0.33±0.29 CC, P=.0090). Graft density, converted in Hounsfield Unit (HU), improved during healing from 322.0±100.42 HU to 1062.0±293.7 HU; difference 740.0±295.35 HU (P=0.0001). The mean ISQ value was 65.5 at implant placement and it increased to 74.1 at the 6-month examination (P=.0014). Twelve out of 18 patients (66.6%) experienced no pain; 10 out of 18 patient experienced no swelling (55.5%). No severe pain or swelling was reported in all of the cases. The mean analgesic tables consuming was 0.78±0.67. Mean surgical time was 24.0±4.07 minutes.
Conclusions and clinical implications
The iRaise Sinus Lift System may provide a new option for minimally invasive transcrestal sinus surgery with minimal patient discomfort. A physiological contraction of 13.9% of its original volume was experienced during healing. Long term clinical studies are needed to confirm these preliminary results.